GTJA Leads $45M Round In Chinese Antibody Drug Developer Akeso

For Digital Subscribers Only

The GTJA Investment Group has led a RMB300 million (US$45 million) series B round in Akeso Biopharma, a Chinese innovative biotechnology company.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

RELATED NEWS



LEAVE A REPLY